pomalidomide has been researched along with Plasma Cell Tumor in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N | 1 |
| Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M | 1 |
| Arima, N; Kawada, H | 1 |
1 review(s) available for pomalidomide and Plasma Cell Tumor
| Article | Year |
|---|---|
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
3 other study(ies) available for pomalidomide and Plasma Cell Tumor
| Article | Year |
|---|---|
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Dexamethasone; Female; Humans; Injections, Spinal; Plasmacytoma; Renal Dialysis; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multimodal Imaging; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Soft Tissue Neoplasms; Thalidomide | 2019 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Transplantation; Nerve Tissue Proteins; Plasmacytoma; Signal Transduction; Thalidomide; Trans-Activators | 2015 |